Rejuvenate Bio Secures $4M Grant for Gene Therapy Development

Rejuvenate Bio receives $4M grant for gene therapy development

Rejuvenate Bio (Linkedin), a biotech company specializing in gene therapies for age-related diseases, has been awarded a $4M grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of RJB-0402, a gene therapy for desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM).

Funding Amount: $4 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Daniel Oliver (CEO Linkedin)

What Rejuvenate Bio needs to buy: Rejuvenate Bio is seeking partnerships with biotech firms, research organizations, manufacturers, and regulatory experts to further develop their gene therapies, ensure reliable production and supply chain management, and navigate the complex regulatory landscape for gene therapies. Companies specializing in research and development, manufacturing, and regulatory compliance are encouraged to explore collaboration opportunities with Rejuvenate Bio.